Product Description
Formulation AC-SD-03 will be moved forward in drug development with an ascending dose study in healthy elderly subjects and a Phase 3 study in mild to moderate AD. AC-SD-03 is a novel proprietary formulation of tricaprilin which has been optimised for safety, tolerability, PK and PD. (Sourced from: https://www.cerecin.com/newsroom/Development-of-tricaprilin.pdf)
Mechanisms of Action: LHRH Analogue
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cerecin
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AC-17-014_BE | P1 |
Completed |
Healthy Volunteers |
2017-04-07 |